Techulon werkt samen met BioConcept voor Europese distributie
Array
Techulon Inc., marktleider in laagtoxische introductie van genetisch materiaal, heeft een overeenkomst getekend met BioConcept uit het Zwitserse Allschwil voor de distributie van Glycofect. Glycofect is een polymerische transfectiereagens voor de introductie van nanodeeltjes. Het wordt gebruikt in meer dan 20 landen door bedrijfs-, universiteits-, en overheidslaboratoria voor geavanceerd onderzoek naar een beter begrip van celbiologie en voor ontwikkeling van nieuwe therapieen op celbasis.
BioConcept is al 30 jaar lang systeemleverancier voor het biologische onderzoek in Zwitserland, en ondersteunt zijn klanten met een complete high-tech portfolio van reagentia, wegwerpproducten, laboratoriumapparatuur en instrumenten voor toepassing in de celbiologie, moleculaire biologie en immunologie.
Engelstalig bericht:
Swiss-based company joins U.S. and Asian distributors for Glycofectâ„¢ reagents
Techulon Inc., the leader in low-toxicity gene delivery has signed a distribution agreement with BioConcept of Allschwil, Switzerland. Glycofect is a polymeric nanoparticle-delivery transfection reagent designed to be particularly effective in primary cells of therapeutic interest. It is being used in over 20 countries by government, university and corporate laboratories for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics.
“BioConcept, leading manufacturer of Swiss made cell culture media (AMIMED®), is proud to be the partner of Techulon for distribution of Glycofect,†said Martin Howald, CEO/President of BioConcept. “The innovative nature of Glycofect perfectly fits BioConcept’s portfolio and the combination of Glycofect with MAM-PF – our chemically defined, protein-, serum- and animal component free CHO production medium, will give our valued customers additional benefits.â€
“We are very pleased to have BioConcept represent Techulon. Swiss and European institutions are leaders in cell-based therapeutics research, and as research focus shifts towards primary cells we expect to see strong growth with our Glycofect reagents,†said Frank Akers, President of Techulon. “We believe that BioConcept has an excellent product portfolio and customer base that will expand our market penetration throughout Europe.â€
About Techulon
Techulon, Inc. is a life sciences company headquartered in Blacksburg, VA, with a core capability in novel biodegradable and low toxicity DNA and RNA delivery reagents for cell-based research and therapeutics. For more information please visit the company website at www.techulon.com.
About BioConcept
BioConcept is a dedicated ‘system supplier’ to the Swiss biological research community since more than 30 years, supporting its customers with a comprehensive and high-tech product portfolio, supplying reagents, disposables, laboratory equipment and instrumentation for applications in the fields of cell biology, molecular biology and immunology. AMIMED® is the registered trademark of BioConcepts cell and tissue culture product line manufactured in Switzerland with focus on Animal Component Free media manufactured according to GMP guidelines. For more information visit the BioConcept website at www.bioconcept.ch
